Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

171.14USD
21 Jul 2014
Price Change (% chg)

$3.74 (+2.23%)
Prev Close
$167.40
Open
$168.04
Day's High
$171.90
Day's Low
$166.34
Volume
2,830,234
Avg. Vol
3,911,274
52-wk High
$174.49
52-wk Low
$86.95

Search Stocks

Latest Key Developments (Source: Significant Developments)

TauTona Group Sells Aline HA to Allergan Inc
Thursday, 17 Apr 2014 08:30am EDT 

TauTona Group:Says its subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.Financial terms of the transaction were not disclosed.  Full Article

Voyant Biotherapeutics, LLC enters into exclusive R&d collaboration agreement with Allergan Inc
Thursday, 20 Feb 2014 04:30pm EST 

Allergan Inc:Says Voyant Biotherapeutics, LLC, has signed an exclusive R&D Collaboration Agreement with Allergan, Inc.Says the agreement provides for a combination of upfront, research and milestone payments.Says under the agreement, the two companies will work together to identify disease-associated pathways and targets for the development of new therapeutic agents to treat ocular disease.  Full Article

Allergan Inc gives FY 2014 guidance in line with analysts' estimates; gives Q1 2014 guidance; EPS guidance below analysts' estimates - Conference Call
Wednesday, 5 Feb 2014 11:00am EST 

Allergan Inc:Expects FY 2014 product net sales in the range of $6.650 billion to $6.950 billion.Expects FY 2014 non-GAAP diluted earnings per share in the range of $5.36 to $5.48.Expects Q1 2014 product net sales in the range of $1.525 billion to $1.600 billion.Expects Q1 2014 non-GAAP diluted earnings per share in the range of $1.09 to $1.12.FY 2014 revenue of $6.801 billion and EPS of $5.45 - Thomson Reuters I/B/E/S.Q1 2014 revenue of $1.597 billion and EPS of $1.19 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc declares fourth quarter dividend
Wednesday, 5 Feb 2014 09:00am EST 

Allergan Inc:Declares a fourth quarter dividend of $0.05 per share.Payable on Mar. 21 to stockholders of record on Feb. 28.  Full Article

Allergan Inc completes sale of obesity intervention business
Monday, 2 Dec 2013 05:00pm EST 

Allergan Inc:Says it has completed the sale of its obesity intervention business to Apollo Endosurgery, Inc.Says it received a cash payment of $75 million and a $15 million minority equity interest in Apollo Endosurgery.  Full Article

Allergan Inc Raises Low End Of Prior FY 2013 Guidance; Issues Q4 2013 Guidance; EPS Guidance Below Analysts' Estimates
Tuesday, 29 Oct 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between $6.125 billion and $6.200 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $4.74 and $4.76. For the fourth quarter of 2013, it expects total product net sales between $1.585 billion and $1.660 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $1.31 and $1.33. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $4.76 for fiscal 2013; revenue of $1.625 billion and EPS of $1.35 for the fourth quarter of 2013.  Full Article

Allergan Inc Declares Dividend
Tuesday, 29 Oct 2013 09:00am EDT 

Allergan Inc announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 11, 2013 to stockholders of record on November 20, 2013.  Full Article

Allergan Inc Receives FDA Approval For Juvederm Voluma XC
Wednesday, 23 Oct 2013 04:51pm EDT 

Allergan, Inc announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM VOLUMA XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. JUVEDERM VOLUMA XC helps create a more youthful appearance to the face and provides natural-looking and long-lasting results up to two years with optimal treatment.  Full Article

Medy Tox Inc Signs Technology Licensing Contract with Allergan, Inc.
Wednesday, 25 Sep 2013 06:05pm EDT 

Medy Tox Inc announced that it has signed a contract with Allergan, Inc., a Delaware-based corporation, and its subsidiaries, Allergan Pharmaceuticals Ireland, a company incorporated in Ireland, and Allergan Pharmaceuticals Holdings (Ireland), an unlimited company incorporated in Ireland (collectively referred to as “Allergan”), for the development and sale of neurotoxin candidate products. Allergan, Inc. was licensed with the exclusive development and distribution right in the United States, and other entities of Allergan will be the exclusive distributor of the Company's products in markets expect Korea. The contract amount is KRW 389,801,600,000 (USD 362,000,000).  Full Article

Allergan Inc Announces FDA Approval Of BOTOX Cosmetic (onabotulinumtoxinA) for Temporary Improvement Of Moderate To Severe Lateral Canthal Lines (Crow's Feet Lines) In Adults
Wednesday, 11 Sep 2013 09:07pm EDT 

Allergan Inc announced approval by the U.S. Food and Drug Administration (FDA) to market BOTOX Cosmetic (onabotulinumtoxinA), for an additional indication to temporarily treat moderate to severe lateral canthal lines, commonly known as 'crow's feet' lines. BOTOX Cosmetic is the first and only product of its kind approved for this indication. BOTOX Cosmetic, approved in the United States in 2002 for the temporary improvement of moderate to severe glabellar lines (frown lines between the brows) for patients aged 18 to 65 years, remains the number-one minimally invasive aesthetic medical treatment globally. The safety and efficacy of BOTOX Cosmetic as a treatment for crow's feet lines was demonstrated in two randomized, multi-center, placebo-controlled clinical trials. The studies enrolled more than 1,350 subjects with 833 subjects receiving treatment with BOTOX Cosmetic. The trial demonstrated that BOTOX Cosmetic was an effective treatment compared to the control group, which did not receive BOTOX Cosmetic treatment.  Full Article

Photo

Allergan to cut 13 percent of jobs in fight against Valeant

- Allergan Inc, which is fighting a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday it would cut 13 percent of its workforce as part of a restructuring meant to boost profits over the next six years.

Search Stocks